Viking Therapeutics gains after initiating Phase 1 trial for new weight-loss drug

Viking Therapeutics

24/06/2026 16:51

June 24 - ** Shares of drug developer Viking Therapeutics VKTX.O up 5.7% at $36.78
** VKTX initiates phase 1 study of a new drug VK3019 for treatment of metabolic disorders and obesity
** VK3019 targets amylin and calcitonin receptors, which can help reduce appetite, control glucose and support weight loss
** Co to initiate phase 3 trial to evaluate oral drug VK2735 for treatment of obesity and overweight later this year
** Including session's moves, stock up 4.49% YTD

(Reporting by Zakia Mariyam in Bengaluru)
((zakia.mariyam@thomsonreuters.com))